Hengrui, Kailera’s oral GLP-1 clears late-stage bar in China but US results still pending at Gabrielle Masson

Location: Unknown.

Employment type: full-time.

Key skills: GLP, Regulatory Affairs.

New data on Hengrui Pharma and Kailera Therapeutics’ investigational oral GLP-1 have validated the late-stage weight loss asset and paved the road for a regulatory submission in China, but analysts pointed to high rates of nausea and vomiting that could challenge the ongoing U.S. study.